Enliven Therapeutics Inc.

NASDAQ: ELVN · Real-Time Price · USD
20.24
0.47 (2.38%)
At close: Aug 15, 2025, 3:45 PM

Enliven Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 316K n/a n/a n/a 440K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a 74K 158K 80K 79K 79K 77K 79K 74K 67K n/a 104K 495K 25K 25K 24K 25K 25K
Gross Profit
n/a -74K 158K -80K -79K -79K 363K -79K -74K -67K n/a -104K -495K -25K -25K -24K -25K -25K
Operating Income
-28.58M -31.69M -26.9M -27.07M -24.6M -25.99M -22.73M -24.25M -20.13M -16.42M -3.26M -10.93M -9.02M -8.68M -8.39M -13.66M -13.17M -10.28M
Interest Income
3.25M 3.2M 3.72M 3.84M 4.09M 3.25M 3.37M 3.49M 3.41M 1.69M 613K 380K 127K 9K 3K 30K 48K 83K
Pretax Income
-25.34M -28.54M -23.18M -23.16M -19.72M -22.74M -19.37M -20.77M -16.72M -14.72M -9.55M -4.61M -11.45M -14.64M -14.32M -13.65M -13.16M -10.26M
Net Income
-25.34M -28.54M -23.18M -23.16M -19.95M -22.74M -19.37M -20.77M -16.72M -14.72M 32.19M -10.55M -8.89M -8.67M -8.39M -13.65M -13.16M -10.26M
Selling & General & Admin
7.09M 6.8M 6.17M 5.81M 5.78M 6.02M 4.82M 4.64M 4.95M 4.54M 1.97M 3.1M 1.08M 1.62M 1.53M 3.24M 3.07M 3.14M
Research & Development
21.49M 24.89M 20.72M 21.26M 18.83M 19.89M 17.83M 19.61M 15.18M 11.88M 180K 7.83M 7.94M 7.06M 6.86M 10.4M 10.07M 7.12M
Other Expenses
n/a n/a -80K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
28.58M 31.69M 26.82M 27.07M 24.6M 25.91M 22.65M 24.25M 20.13M 16.42M 3.26M 10.93M 9.02M 8.68M 8.39M 13.63M 13.14M 10.26M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -24K -25K -25K
Cost & Expenses
n/a 31.69M 26.9M 27.07M 24.6M 25.99M 22.73M 24.25M 20.13M 16.42M 3.26M 10.93M 9.02M 8.68M 8.39M 13.66M 13.17M 10.28M
Income Tax Expense
n/a n/a n/a n/a 232K n/a n/a n/a -48.09K n/a 88K 242K -443K 14K 8K 12K 8K 23K
Shares Outstanding (Basic)
52.11M 50.05M 49.86M 48.27M 48.08M 42.05M 41.13M 41.03M 40.96M 18.52M 6.57M 6.57M 6.57M 6.57M 6.57M 6.22M 4.43M 4.39M
Shares Outstanding (Diluted)
52.11M 50.05M 49.86M 48.27M 48.08M 42.05M 41.13M 41.03M 40.96M 18.52M 6.57M 6.57M 6.57M 6.57M 6.57M 6.22M 4.43M 4.39M
EPS (Basic)
-0.49 -0.57 -0.46 -0.48 -0.41 -0.54 -0.47 -0.51 -0.41 -0.8 4.90 -0.7 -1.74 -2.23 -2.18 -2.19 -2.97 -2.33
EPS (Diluted)
-0.49 -0.57 -0.46 -0.48 -0.41 -0.54 -0.47 -0.51 -0.41 -0.8 4.90 -0.7 -1.74 -2.23 -2.18 -2.19 -2.97 -2.33
EBITDA
-28.58M -31.69M -26.82M -26.99M -24.52M -25.91M -22.65M -24.17M -20.06M -16.35M -10.1M -10.87M -8.96M -8.64M -8.36M -13.62M -13.14M -10.23M
EBIT
n/a -28.54M -26.9M -27.07M -24.6M -25.99M -22.73M -24.25M -18.83M -16.42M -10.16M -10.93M -9.02M -8.68M -8.39M -13.65M -13.16M -10.26M
Depreciation & Amortization
n/a 74K 80K 80K 78K 79K 77K 78K 74K 67K 64K 104K 495K 25K 25K 24K 25K 25K